tailieunhanh - Impact of the line of treatment on progression-free survival in patients treated with T-DM1 for metastatic breast cancer

Trastuzumab emtansine (T-DM1) is indicated as second-line treatment for human epidermal growth factor receptor 2 (HER2)-positive metastatic or unresectable locally advanced breast cancer, after progression on trastuzumab and a taxane-based chemotherapy. |

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN